Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
Standard
Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment. / Kriegsmann, Katharina; Hundemer, Michael; Hofmeister-Mielke, Nicole; Reichert, Philipp; Manta, Calin-Petru; Awwad, Mohamed H S; Sauer, Sandra; Bertsch, Uta; Besemer, Britta; Fenk, Roland; Hänel, Mathias; Munder, Markus; Weisel, Katja C; Blau, Igor W; Neubauer, Andreas; Müller-Tidow, Carsten; Raab, Marc S; Goldschmidt, Hartmut; Huhn, Stefanie; For The German-Speaking Myeloma Multicenter Group Gmmg.
In: CANCERS, Vol. 12, No. 8, 18.08.2020.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Comparison of NGS and MFC Methods: Key Metrics in Multiple Myeloma MRD Assessment
AU - Kriegsmann, Katharina
AU - Hundemer, Michael
AU - Hofmeister-Mielke, Nicole
AU - Reichert, Philipp
AU - Manta, Calin-Petru
AU - Awwad, Mohamed H S
AU - Sauer, Sandra
AU - Bertsch, Uta
AU - Besemer, Britta
AU - Fenk, Roland
AU - Hänel, Mathias
AU - Munder, Markus
AU - Weisel, Katja C
AU - Blau, Igor W
AU - Neubauer, Andreas
AU - Müller-Tidow, Carsten
AU - Raab, Marc S
AU - Goldschmidt, Hartmut
AU - Huhn, Stefanie
AU - For The German-Speaking Myeloma Multicenter Group Gmmg, null
PY - 2020/8/18
Y1 - 2020/8/18
N2 - In order to meet the challenges in data evaluation and comparability between studies in multiple myeloma (MM) minimal residual disease (MRD) assessment, the goal of the current study was to provide a step-by-step evaluation of next-generation sequencing (NGS) and multicolor flow cytometry (MFC) data. Bone marrow (BM) sample pairs from 125 MM patients were analyzed by NGS and MFC MM MRD methods. Tumor load (TL) and limit of detection (LOD) and quantification (LOQ) were calculated. The best-fit MRD cut-off was chosen as 1 × 10-5, resulting in an overall 9.6% (n overall = 12 (NGS n = 2, MFC n = 10)) nonassessable cases. The overall concordance rate between NGS and MFC was 68.0% (n = 85); discordant results were found in 22.4% (11.2% (n = 14) of cases in each direction. Overall, 55.1% (n = 60/109) and 49.5% (n = 54/109) of patients with a serological response ≥ very good partial response (VGPR) showed BM MRD negativity by NGS and MFC, respectively. A good correlation in the TL assessed by both techniques was found (correlation coefficient = 0.8, n = 40, p < 0.001). Overall, our study shows good concordance between MM BM MRD status and TL when comparing NGS and MFC at a threshold of 10-5. However, a sufficient number of analyzed events and calculation of MRD key metrics are essential for the comparison of methods and evaluability of data at a specific MRD cut-off.
AB - In order to meet the challenges in data evaluation and comparability between studies in multiple myeloma (MM) minimal residual disease (MRD) assessment, the goal of the current study was to provide a step-by-step evaluation of next-generation sequencing (NGS) and multicolor flow cytometry (MFC) data. Bone marrow (BM) sample pairs from 125 MM patients were analyzed by NGS and MFC MM MRD methods. Tumor load (TL) and limit of detection (LOD) and quantification (LOQ) were calculated. The best-fit MRD cut-off was chosen as 1 × 10-5, resulting in an overall 9.6% (n overall = 12 (NGS n = 2, MFC n = 10)) nonassessable cases. The overall concordance rate between NGS and MFC was 68.0% (n = 85); discordant results were found in 22.4% (11.2% (n = 14) of cases in each direction. Overall, 55.1% (n = 60/109) and 49.5% (n = 54/109) of patients with a serological response ≥ very good partial response (VGPR) showed BM MRD negativity by NGS and MFC, respectively. A good correlation in the TL assessed by both techniques was found (correlation coefficient = 0.8, n = 40, p < 0.001). Overall, our study shows good concordance between MM BM MRD status and TL when comparing NGS and MFC at a threshold of 10-5. However, a sufficient number of analyzed events and calculation of MRD key metrics are essential for the comparison of methods and evaluability of data at a specific MRD cut-off.
U2 - 10.3390/cancers12082322
DO - 10.3390/cancers12082322
M3 - SCORING: Journal article
C2 - 32824635
VL - 12
JO - CANCERS
JF - CANCERS
SN - 2072-6694
IS - 8
ER -